ADIAL PHARMACEUTICALS INC (ADIL) Forecast, Price Target & Analyst Ratings

Name: ADIAL PHARMACEUTICALS INC (ADIL) Analyst Consensus Rating
Brand: ADIAL PHARMACEUTICALS INC
Rating: 8 (9 reviews)

NASDAQ:ADIL • US00688A3041

1.84 USD

-0.16 (-8%)

Last: Mar 23, 2026, 08:00 PM

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ADIAL PHARMACEUTICALS INC (ADIL).

Consensus Price Target

Price Target

$26.52

+ 1,341.30% Upside

→ Price target details

Next Earnings Forecast

Earnings Estimate

Release Date: May 12, 2026
Period: Q1 / 2026
EPS Estimate: -$2.63
Revenue Estimate

→ Full earnings forecast details

ChartMill Buy Consensus

Rating

82.22%

Weighted Analyst Rating Score

→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target

$26.52

Upside

+ 1,341.30%

From current price of $1.84 to mean target of $26.52, Based on 9 analyst forecasts

Low

$8.08

Median

$20.40

High

$52.50

Price Target Revisions

1 Month

1,099.98%

3 Months

1,099.98%

Price Target Summary

9 Wall Street analysts provided a forecast for the next 12 months for ADIL. The average price target is 26.52 USD. This implies a price increase of 1341.3% is expected in the next year compared to the current price of 1.84.

The average price target has been revised upward by 1099.98% in the past 3 months.

→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

Analyst Ratings History

Analyst Ratings Consensus

ChartMill Buy Consensus

82.22%

ADIL was analyzed by 9 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about ADIL.

In the previous month the buy percentage consensus was at a similar level.

ADIL was analyzed by 9 analysts. More opinions would make the average more meaningful.

→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

Date	Firm	Action	From → To
2025-09-30	Maxim Group	Upgrade	Hold -> Buy
2024-11-14	Rodman & Renshaw	Initiate	Buy
2023-07-11	Brookline Capital	Reiterate	Buy -> Buy
2022-08-17	Maxim Group	Downgrade	Buy -> Hold
2021-10-13	Brookline Capital	Initiate	Buy
2021-06-29	Litchfield Hills	Initiate	Buy

Next Earnings Forecast Details

Next Earnings Details

Release Date: May 12, 2026
Period: Q1 / 2026
EPS Estimate: -$2.63
Revenue Estimate
Revenue Q2Q: N/A
EPS Q2Q: -674.00%
Number of Analysts: 4

Next Earnings Revisions

Revenue (1 Month)

N/A

Revenue (3 Months)

N/A

EPS (1 Month)

-2,480.00%

EPS (3 Months)

-2,480.00%

Next Earnings Summary

ADIL is expected to report earnings on 5/12/2026. The consensus EPS estimate for the next earnings is -2.63 USD and the consensus revenue estimate is 0 USD.

→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2026 - 2033

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033
Revenue YoY % growth												N/A	N/A	N/A	N/A -100.00%	N/A	N/A 59.59%	N/A 75.84%	N/A 30.88%
EBITDA YoY % growth	-800K	-410K 48.75%	-1M -143.90%	-6.99M -599.00%	-8.24M -17.88%	-10.93M -32.65%	-17.73M -62.21%	-13.31M 24.93%	-6.887M 48.25%	-8.284M -20.28%	-7.799M 5.85%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EBIT YoY % growth	-800K	-410K 48.75%	-1M -143.90%	-6.99M -599.00%	-8.24M -17.88%	-10.93M -32.65%	-17.74M -62.31%	-13.32M 24.92%	-6.888M 48.29%	-8.285M -20.27%	-7.8M 5.85%	N/A -39.82%	N/A -55.49%	N/A -34.89%	N/A -23.51%	N/A 129.01%	N/A 221.64%	N/A 170.85%	N/A 49.29%
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS YoY % growth	N/A	N/A	N/A	N/A	N/A	-0.86	N/A -71,062.79%	-13.00 97.88%	-4.32 66.77%	-1.94 55.09%	-9.91 -410.82%	N/A -4.47%	N/A 11.33%	N/A 93.67%	N/A -64.04%	N/A 152.94%	N/A 159.60%	N/A 229.96%	N/A 48.82%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

	Q1 / 26	Q2 / 26	Q3 / 26	Q4 / 26	Q1 / 27	Q2 / 27	Q3 / 27	Q4 / 27
EPS Q2Q % growth	-2.63 -674.00%	-0.10 97.85%	-0.10 94.90%	-0.10 96.84%	-0.13 94.96%	-0.14 -47.37%	-0.12 -20.00%	-0.13 -36.84%
Revenue Q2Q % growth					N/A	N/A	N/A	N/A
EBITDA Q2Q % growth	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EBIT Q2Q % growth	-2.529M -11.55%	-2.721M -44.52%	-2.911M -65.02%	-2.981M -58.11%	-4.066M -60.76%	-4.242M -55.91%	-4.596M -57.88%	-4.773M -60.10%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year

24.75%

EPS Next 5 Year

15.45%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year

N/A

Revenue Next 5 Year

N/A

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year

N/A

EBIT Next 5 Year

N/A

→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

ADIAL PHARMACEUTICALS INC / ADIL Forecast FAQ

Can you provide the average price target for ADIAL PHARMACEUTICALS INC stock?

9 analysts have analysed ADIL and the average price target is 26.52 USD. This implies a price increase of 1341.3% is expected in the next year compared to the current price of 1.84.

Can you provide the upcoming earnings date for ADIAL PHARMACEUTICALS INC?

ADIAL PHARMACEUTICALS INC (ADIL) will report earnings on 2026-05-12.

What are the consensus estimates for ADIAL PHARMACEUTICALS INC (ADIL) next earnings?

The consensus EPS estimate for the next earnings of ADIAL PHARMACEUTICALS INC (ADIL) is -2.63 USD and the consensus revenue estimate is 0 USD.

Can you provide the analyst count for ADIAL PHARMACEUTICALS INC stock?

The number of analysts covering ADIAL PHARMACEUTICALS INC (ADIL) is 9.

Analyst forecast overview

Forecast Snapshot